Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study. This is an ASCO Meeting ...
Impact of KRAS mutation status on outcomes in peritoneal metastatic mucinous adenocarcinoma of the colon and appendix following CRS-HIPEC: A retrospective analysis. The addition of monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results